Coya Therapeutics, Inc.(COYA)
$3.27+0.06 (+1.87%)
COYA
Coya Therapeutics, Inc. stock drug pipeline
$3.27
At close:+0.06 (+1.87%)
Want to see COYA full AI Analyst Report?
Coya Therapeutics, Inc. (COYA) Drug Pipeline
129 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| COYA 302 | Amyotrophic Lateral Sclerosis (Als) | Phase II | Recruiting | Study of COYA 302 for the Treatment of ALS | Aug 31, 2025 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| COYA 302 | Phase II | Amyotrophic Lateral Sclerosis (Als) | Recruiting | Study of COYA 302 for the Treatment of ALS | Aug 31, 2025 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Coya Therapeutics, Inc. (COYA) have in its pipeline
Coya Therapeutics, Inc. COYA is currently developing the following drugs: COYA 302. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
